Catalyst Event
Pfizer Inc (PFE) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
5/13/2026, 12:00:00 AM
The European Commission granted marketing authorization for HYMPAVZI (marstacimab) on 2026-05-13 for the treatment of adults and adolescents with hemophilia A or B with inhibitors (Low importance as a standard regulatory approval).
Korean Translation
2026년 5월 13일, 유럽연합 집행위원회는 억제인자를 보유한 혈우병 A 또는 B 성인 및 청소년 환자 치료를 위한 힘파브지(HYMPAVZI, marstacimab)의 판매를 승인함(통상적인 규제 승인에 따른 낮은 영향 예상).
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
6/1/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast revenue of 7.52B HKD. Estimated Medium importance as earnings results typically drive significant price movement scheduled.
5/27/2026, 12:00:00 AM